AIM ImmunoTech Inc presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship drug Ampligen (rintatolimod) as a component of a Chemokine Modulatory (CKM) regimen for the treatment of colorectal cancer metastatic to the liver at the six-day annual meeting of the American Association for Cancer Research (AACR), which kicked off on April 8, in New Orleans, Louisiana. The Ocala, Florida-based immuno-pharma company said based on preclinical data showing the prognostic value of intratumoral CD8+ T cell (CTL) in colorectal cancer outcomes, it was hypothesized that “systemic infusion” of the combination of IFNα-2b with Ampligen (selective TLR3 ligand for IV use) could “reprogram” the local balance between the CTL and regulatory T cell (Treg)-attracting chemokines and the resulting patterns of immune infiltrates in liver tumors.
Cloud DX (TSX-V:CDX, OTCQB:CDXFF) Inc announced a new contract with a primary care clinic in Erie, Pennsylvania. The virtual healthcare company said the clinic will use and deploy Cloud DX's Connected Health kits to remotely monitor and support its patients with chronic illnesses, representing over 1,000 of its 2,500 patient load.
XPhyto Therapeutics Corp provided a product development report on its sublingual oral dissolvable film (ODF) biosensor development pipeline, noting that the “integration” of its wholly-owned German subsidiary, Vektor Pharma TF GmbH, and recently acquired 3a technologies, has created a “pipeline of rapid screening test products” with “near-term commercialization potential.” The company's oral dissolvable products are based on the ODF platform technology developed by Baden-Württemberg-based Vektor, which incorporates proprietary biosensor molecules developed by XPhyto's recently acquired and wholly-owned Germany subsidiary, 3a-diagnostics GmbH, which is located southeast of Stuttgart, Germany.
Kintara Therapeutics (NASDAQ:KTRA) Inc presented data at the 2022 American Association for Cancer Research (AACR) Annual Meeting. Kintara observed enhanced drug concentrations of VAL-083 in the brain and GBM brain tumors in comparison to circulating plasma concentrations in human clinical trials. The company highlighted that most therapeutic agents targeting brain tumors have very limited access to primary brain tumors due to the protective nature of the BBB that limits access for most chemical structures. The company presented laboratory studies on three glucose transporters that were studied in vitro, including SGLT1, SGLT2 and GLUT1. For all three transporters VAL-083 was not a substrate for these active transport systems, which Kintara suggests could indicate that VAL-083 may be crossing the BBB by passive diffusion rather than facilitated active transport.
Empower Clinics Inc told investors it plans to host a ribbon cutting ceremony and open house when it opens its eighth and flagship clinic in the Greater Toronto area under its The Medi-Collective (TMC) brand. The 3,500 square feet (sq ft) Etobicoke clinic will offer family medicine and serve as a hub for tele-dermatology in partnership with MedX Health Corp and paramedical services such as chiropractor and physiotherapy. The centre will have four family doctors and there are plans to hire general practice and specialist physicians to offer additional services in coming months, Empower said.
Biocept Inc has announced that it has granted inducement stock options to purchase an aggregate of 519,140 shares of its common stock to 44 new employees, including an inducement stock option to purchase 150,000 shares of its common stock to its new chief operations officer, Philippe Marchand. The company said the options have an exercise price of $2.32 per share, the closing price of its common stock on March 31, 2022, are non-qualified stock options, have a ten-year term and vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal monthly installments over the following 36 months, subject to the new employees' continued service with Biocept through the applicable vesting dates.
Guardforce AI (NASDAQ:GFAI) Company Limited an integrated security solutions provider, said it has closed the previously announced securities purchase agreement with certain institutional investors to purchase approximately $10.0 million worth of its ordinary shares in a registered direct offering. Under the agreement, the company sold about 8.7 million of its ordinary shares at a price of $1.15 per share. The gross proceeds to the company from the registered direct offering are estimated to be approximately $10.0 million, before deducting the placement agent's fees and other estimated offering expenses.
Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) told investors its 100%-owned Segilola Gold Mine in Nigeria continued to operate at a steady state, with above design mill throughput, in March 2022. Total gold production was 7,220 ounces during the month, taking production for the first quarter of the year to 21,343 ounces. Recovery in March averaged 95.1% with average recovery for 1Q at 94.1%. "The month of March has closed off a very positive start to the year, completing our first full quarter of gold production,” president and CEO Segun Lawson said in a statement. “There continues to be production improvements in all aspects, in particular, with recoveries continuing to improve and averaging 95.1% for the month of March.” The company sold 16,658 ounces of gold and 922 ounces of silver during the quarter, with exports occurring regularly throughout the period, Thor said.
enCore Energy Corp has hailed the latest drill results from its Rosita South project, which have underscored the potential to discover future uranium resources across the entire Texas property. So far, 32 holes, for around 11,000 feet (ft), have been reported and eight mineralized sands plus a potential further four have been identified, all within 800 ft of the surface. The drilling has also established an extension of mineralization in the so-called production area, supporting a start-up of the past-producing in-situ recovery (ISR) Rosita plant in 2023.
PyroGenesis Canada Inc CEO P. Peter Pascali has filed an updated early warning report on his proposed sale of 750,000 shares in the company. The report, filed on April 9, 2022, concerns the sale of shares in Pyrogenesis held by Fiducie de Credit Mellon Trust and will be effected at prevailing market prices during April 18, 2022 to May 6, 2022. As of April 8, 2022 Pascali’s total ownership is,79,744,498 common shares, or 46.87% of the issued and outstanding shares of the company. If the proposed sales goes through his holdings drop to 78,994,498 shares, representing 46.43%.
Xigem Technologies (CSE:XIGM, OTCQB:XIGMF) Corporation, a technology provider for the emerging remote economy, announced that it has filed the Business Acquisition Report (BAR) associated with its previously announced purchase of Cylix Data. It also provided an update on the status of other strategic initiatives, including the proposed acquisition of the All Source B2B software platform. "In our first year as a publicly listed company we were very active in evaluating technologies to add to our portfolio," said Brian Kalish, co-founder and chief executive officer of Xigem.
Tiidal Gaming Group Corp (CSE:TIDL) told investors that its shares have started trading on the OTCQB Venture Market today, April 11, 2022, under the ticker symbol TIIDF. Additionally, the company said it is applying for eligibility for book-entry delivery and depository services of Depository Trust Company, to facilitate electronic settlement of transfers of its shares in the US. This electronic method of clearing securities expedites the receipt of stock and cash and accelerates the settlement process for investors. "Listing on the OTCQB positions Tiidal Gaming with increased visibility among the American investment community and improved liquidity for our current and prospective shareholders," CEO Tom Hearne said in a statement. The company also announced that Carlo Rigillo, a chartered professional accountant with two decades of financial and public markets experience, will become its chief financial officer effective today.
Trust Stamp (NASDAQ:IDAI, EURONEXT:AIID) has announced the winners of the 2022 Trusted Rwanda Hackathon following a hybrid event pitting five finalists. Their challenge was to leverage Trust Stamp (NASDAQ:IDAI, EURONEXT:AIID)'s secure identity and data tokenization technology, through simple API integration, transforming the firm’s technology solutions in Africa while also considering factors including biometrics, regulatory compliance, privacy and cyber security. iLabs International/Uqu.do was adjudged the winner for its proposed privacy-preserving cross-border identity wallet ecosystem with EU-Africa interoperability. The digital identity company wins access to Trust Stamp (NASDAQ:IDAI, EURONEXT:AIID)'s APIs and development support to bring the innovation to life.
Electra Battery Materials Corporation (TSX-V:ELBM, OTCQX:ELBMF) said it remains on schedule to commission North America's first battery-grade cobalt sulfate refinery - the second largest outside of China - in December 2022. Electra is planning to build a fully integrated, localized and environmentally sustainable battery materials park north of Toronto. Leveraging the company's own mining assets and business partners, the Electra Battery Materials Park is expected to host cobalt and nickel sulfate production plants, a large-scale lithium-ion battery recycling facility, and battery precursor materials production, which will serve both North American and global customers.
Emmaus Life Sciences Inc, a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced that it has launched an innovative full-service telehealth solution with its strategic partners, including Asembia LLC, US Bioservices Corporation and UpScript IP Holdings, LLC. The telehealth program capitalizes on the expansion of telemedicine in the US to afford patients and providers online access to Endari, Emmaus' prescription-grade L-glutamine oral powder for the treatment of sickle cell disease.
Argentina Lithium & Energy Corp (TSX-V:LIT, OTCQB:PNXLF) has announced that it has entered into an option agreement with a local vendor to earn a 100% interest in three granted mine concession properties totaling 5,411 hectares in the Salar de Antofalla in Catamarca Province, Argentina. Argentina Lithium's Antofalla North project includes both 100% held and optioned properties. With this new option, the company now controls 14,987 hectares of mining leases in the salt flat, distributed between the adjacent provinces of Salta and Catamarca.
Blue Sky Uranium Corp announced that it is resuming its 4,500 metre (m) exploration drilling program with new holes planned at the Ivana Central target, located 10 kilometres north of the company's Ivana deposit at its Amarillo Grande uranium-vanadium project in Argentina. Blue Sky said six holes totaling 286m were drilled at Ivana Central in 2020 before the program was paused, leaving about 1,200m to be completed at this target.
Adastra Holdings (CSE:XTRX) Ltd has announced that it submitted its Medical Sales License application to Health Canada on April 1, 2022. The Langley, British Columbia-based company reminded investors that in August 2021 it announced its acquisition of 1225140 BC Ltd, doing business as PerceiveMD, a lean digital patient care platform providing complimentary assessments for alternative treatments of medical cannabis and other breakthrough therapies such as psychedelics.
Blue Sky Uranium CEO Nikolaos Cacos talks to The Ellis Martin Report about the exploration and development of uranium and vanadium with a land package of more than 4,000 square kilometers m in nuclear friendly Argentina. Blue Sky Uranium’s mission is to deliver exceptional returns to shareholders by acquiring, exploring, and advancing towards production a portfolio of uranium-vanadium projects, with an emphasis on near-surface deposits with the potential for near-term low-cost production. . Investors can listen to the interview here.
Wishpond Technologies Ltd. (TSX-V:WISH, OTCQX:WPNDF) told investors it expects to release its audited annual financial statements for the year ended December 31, 2021 on April 27, 2022. The company will host a conference call the same day at 10:00am PT/1:00pm ET to discuss the results. The call will be hosted by chairman and CEO Ali Tajskandar, chief financial officer David Pais, and head of investor relations Pardeep S. Sangha. Dial-in details are: 1-778-907-2071 (Vancouver local) and 1-647-374-4685 (Toronto local). Registration for the webinar can be found by following this link, using Meeting ID #: 813 7792 9468.
District Metals Corp has announced that it has commenced core drilling at its high-grade polymetallic Tomtebo property located in the Bergslagen Mining District in south-central Sweden. The Vancouver-based developer of prospective mineral properties said GEOPS-Bolkan Drilling Services Ltd has been awarded the contract for the drill program, which will comprise 1,200 metres (m) in three holes, followed by drilling 1,800m in 10 holes at the Gruvberget property located 40 kilometres (km) northwest from Tomtebo. Drill permitting for 800m in two holes at the company’s Bakar Copper property on Northern Vancouver Island continues and drilling may commence in June or July 2022.
Milestone Scientific Inc (NYSE:MLSS), the medtech group, revealed that it has begun selling its CompuFlo Epidural and CathCheck Verification System disposables to a leading northeast medical center following a successful trial by the latter. "We are honored to announce adoption of our CompuFlo Epidural and CathCheck Verification System by another leading medical center," said Arjan Haverhals, the CEO of Milestone Scientific. "This approval follows a thorough trial and evaluation, which further validates the safety and efficacy of our technology."
Star Royalties Ltd (TSX-V:STRR) said its subsidiary Green Star Royalties Ltd (TSX-V:STRR) has dramatically expanded its carbon credit agreement with Blue Source LLC. The two companies will create verified carbon offset credits to reward the adoption of regenerative agriculture practices by North American farmers. Under the amended agreement, Green Star has agreed to finance Bluesource’s regenerative agriculture carbon offset program up to $20.6 million in cash. The cash will be made available to growers in the program through Locus AG’s CarbonNOW program.
SoLVBL Solutions Inc announced that it has hired industry veteran Jim Slinowsky as director of product development. The Toronto, Ontario-based company noted that Slinowsky brings more than 25 years of North American technology industry experience to SoLVBL's product team. At SoLVBL, he will contribute to the development of new data authentication and cybersecurity products for the financial services, health care services and law enforcement industry verticals, it added. Prior to joining SoLVBL, Slinowsky led product management for Siemens RUGGEDCOM, a portfolio of rugged networking products focused on mission-critical applications in harsh environments. Prior to Siemens, he was director of product management for Powerwave Technologies and held multiple senior engineering and product management roles within Nortel Networks.
DGTL Holdings Inc has appointed veteran finance executive Christopher Foster as its new CFO. Calling him an experienced CFO, DGTL said that Foster will manage all financial controllers at the subsidiary level and will work with appointed auditors to prepare quarterly and annual financial statements. The new CFO has led financial management teams for several public, and private companies, across a range of industries.
Context Therapeutics (NASDAQ:CNTX) Inc announced what it called “encouraging” preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s lead clinical program. Context said the lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrated strong efficacy across multiple PR+ solid tumor models.